December 11, 2015

December 11, 2015

TBK1 protein plays vital role in the process of cell division
News Medical – Dec. 11
Moffitt Cancer Center researchers have found that a protein called TBK1 plays an important role in the process of cell division, especially at a stage called mitosis. 

What the media got wrong about Jimmy Carter’s cancer “cure”
Health News Review – Dec. 10
What’s more, as NBC pointed out in its coverage, there’s no way of knowing whether it’s the drug or the radiation therapy and surgery that cleared all detectable traces of President Carter’s cancer. MedPageToday drove this point home with a number of quotes from cancer experts, including this one from Vernon K. Sondak, MD, of Moffitt Cancer Center in Tampa, Florida. 

Moffitt Cancer Center researchers discover novel role of TBK1 protein in cell division
Health Medicine Network – Dec. 10
Moffitt Cancer Center researchers have found that a protein called TBK1 plays an important role in the process of cell division, especially at a stage called mitosis. 

Genetic Test Finds Radiation Sensitivity Differs Between Primary Tumor and Metastatic Sites
Journal of the National Cancer Institute – Dec. 10
“Right now, we know clinically that patients have different responses to radiation, but the way we treat them doesn’t acknowledge that,” said study coauthor Javier F. Torres-Roca, M.D., a radiation oncologist at the Moffitt Cancer Center and Research Institute in Tampa, Fla. 

A dietary sugar that may prevent melanoma from metastasizing
Medical Xpress – Dec. 10
"Many patients develop resistance to current melanoma drugs. If we can add something like L-fucose to enhance these therapies, that's very exciting, and it's something we're actively looking into," said lead author Eric Lau, Ph.D., who is extending studies on the role of L-fucose in melanoma at the H. Lee Moffitt Cancer Center in Tampa, Florida,

Blockade With Keytruda Combo Shows Anti-MM Activity
MedPage Today – Dec. 9
"This study breaks some exciting frontiers in multiple myeloma in bringing checkpoint inhibitors into our state," said Shain who is also director of the Moffitt Myeloma Working Group. 

First year effort a success for local cancer awareness group
TBO.com – Dec. 9
Organizers of Chipping Away at Prostate Cancer Charity Golf Scramble recently raised $10,000 to benefit prostate cancer awareness and research, and the recipient of those funds was Moffitt Cancer Center of Tampa.

Dietary sugar may help to treat melanoma
News-Medical – Dec. 9
"Many patients develop resistance to current melanoma drugs. If we can add something like L-fucose to enhance these therapies, that's very exciting, and it's something we're actively looking into," said lead author Eric Lau, Ph.D., who is extending studies on the role of L-fucose in melanoma at the H. Lee Moffitt Cancer Center in Tampa, Florida.

A spoonful of ‘sugar’ could help fight cancer
Fortune – Dec. 9
But “don’t go out and start drinking seaweed smoothies thinking that you’re going to stop your cancer,” cautions Eric Lau, a researcher at Moffitt Cancer Center who co-authored the study while at Sanford Burnham Prebys Medical Discovery Institute.

Most experts not surprised by Carter’s status
MedPage Today – Dec. 8
"If I had a patient of my own with four small brain mets undergoing [stereotactic radiation therapy], I would tell them that I fully expected the radiation to take care of those four lesions," said Vernon K. Sondak, MD, of Moffitt Cancer Center in Tampa. "The fact that President Carter reports that it has done just that is not a surprise to me at all.

New cancer drug being used at Moffitt Cancer Center
WFLA – Dec. 8
Dr. Amod Sarnaik with the Moffitt said, “we can’t really declare them cured because there could still be microscopic cancer lurking that rears its ugly head in the future even if a patient is rendered free of disease they still have to be under close surveillance.”

Former President Jimmy Carter announced on Sunday that his cancer is gone
Herald Recorder – Dec. 8
“If I had a patient of my own with four small brain mets undergoing [stereotactic radiation therapy], I would tell them that I fully expected the radiation to take care of those four lesions,” said Vernon K. Sondak, MD, of Moffitt Cancer Center in Tampa. “The fact that President Carter reports that it has done just that is not a surprise to me at all.

Fanning Reappointed, Host Reelected and Smith Elected to the Federal Reserve Bank of Atlanta's Board of Directors
Savannah CEO – Dec. 8
Smith's directorships include Hilton Worldwide Holding Inc., Big Brothers, Big Sisters of America and H. Lee Moffitt Cancer Center & Research Institute (Tampa, Fla.). 

Gifts for children in need
Bay News 9 – Dec. 7
Students got to see Moffitt's research labs and occupational therapy department and spoke with some of the doctors. 

Former President Jimmy Carter Has No Detectable Cancer
Medscape – Dec. 7
"Older patients should not be written off cancer treatments just because of their age," said Lodovico Balducci, MD, from the Moffitt Cancer Center in Tampa, Florida, in an NBC news report.

Former President Jimmy Carter Says His Brain Cancer Is Gone
The Oceanside Post – Dec. 7
"Usually for a person with metastatic disease in the brain, the person would be dead in a few months", said Sondak, chair of the department of cutaneous oncology at Moffitt Cancer Center in Tampa. 

Venetoclax produces durable responses in high-risk CLL
HemOnc Today – Dec. 7
This is just the beginning, and this is a great first step. But we will be even more excited about further data combining venetoclax with monoclonal antibodies. – Javier Pinilla-Ibarz, MD, PhD – Moffitt Cancer Center

Daratumumab combination confers durable responses in relapsed, refractory multiple myeloma
HemOnc Today – Dec. 6
In the last few weeks, an explosion of drugs have been approved for multiple myeloma. These drugs provide great opportunities for patients and clinicians, in terms of improving outcomes and survival. – Kenneth Shain, MD, PhD, Moffitt Cancer Center

Ixazomib prolongs PFS in relapsed, refractory multiple myeloma
HemOnc Today – Dec. 6
Although we have had overlapping classes of proteasome inhibitors, ixazomib (Ninlaro, Takeda Pharmaceuticals) represents the first approved oral proteasome inhibitor in myeloma. It is very exciting for our patients. – Kenneth Shain, MD, PhD, Moffitt Cancer Center

Genetically engineered T cells effective for B-cell malignancies post allogeneic HSCT
HemOnc Today – Dec. 5
In terms of outcomes, acute lymphoblastic leukemia remains the most susceptible disease to CD19-targeted allogeneic CAR T-cell therapy. – Marco L. Davila, MD, PhD, Moffitt Cancer Center

In Jimmy Carter’s cancer treatment, drug could be a game changer
Atlanta Journal Constitution – Dec. 6
“In the past, we didn’t have the tools. Usually for a person with metastatic disease in the brain, the person would be dead in a few months,” said Sondak, chair of the department of cutaneous oncology at Moffitt Cancer Center in Tampa. The spread of melanoma to the brain has been one of the disease’s “Achilles heels,” Sondak said.

Woman finding joy one day at a time after cancer battle
TBO.com – Dec. 6
Then came the cancer. In a whirlwind that began only days before school resumed in August 2014 flew the bad mammogram, the alarming biopsy, the mastectomy at Moffitt Cancer Center and the six months of chemotherapy.

Cancer survivors must make decisions on fertility issues
Orlando Sentinel – Dec. 6
While some argue that parents should have the power to make that decision for their child, "another faction of ethicists believe that they're creating an unhealthy dynamic for the child by putting an undue burden on the child to produce grandchildren," said Dr. Gwendolyn Quinn, a research scientist and expert on survivorship at the Moffitt Cancer Center in Tampa. 

###

Please note we cannot guarantee the accuracy or availability of links. The stories belong to the respective publishers, and links may expire. Some news sites require you to register and select a password in order to retrieve articles, but most usually do not charge a fee to retrieve these news stories.